Trial · NCT03420781
Results by group251
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 251
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period | Treatment Period: Placebo | Baseline | 24.9 | Standard Deviation 5.65 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period | Treatment Period: Relamorelin 10 μg | Baseline | 24.8 | Standard Deviation 6.28 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period | Treatment Period: Placebo | Change from Baseline to Week 12 | -11.9 | Standard Deviation 9.43 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period | Treatment Period: Relamorelin 10 μg | Change from Baseline to Week 12 | -11.2 | Standard Deviation 9.00 | score on a scale |
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Placebo | 29.4 | percentage of participants | ||
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Relamorelin 10 μg | 21.4 | percentage of participants | ||
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Placebo | 46.0 | percentage of participants | ||
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Relamorelin 10 μg | 43.2 | percentage of participants | ||
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Placebo | 40.4 | percentage of participants | ||
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Relamorelin 10 μg | 39.7 | percentage of participants | ||
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Placebo | 38.3 | percentage of participants | ||
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Relamorelin 10 μg | 38.4 | percentage of participants | ||
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Placebo | 36.6 | percentage of participants | ||
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | Treatment Period: Relamorelin 10 μg | 36.2 | percentage of participants | ||
| Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period | Treatment Period: Placebo | Baseline | 24.9 | Standard Deviation 5.65 | score on a scale |
| Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period | Treatment Period: Relamorelin 10 μg | Baseline | 24.8 | Standard Deviation 6.28 | score on a scale |
| Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period | Treatment Period: Placebo | Change from Baseline to Week 40 | -13.3 | Standard Deviation 10.22 | score on a scale |
| Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period | Treatment Period: Relamorelin 10 μg | Change from Baseline to Week 40 | -12.3 | Standard Deviation 9.20 | score on a scale |
| Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period | Treatment Period: Placebo | 19.1 | percentage of participants | ||
| Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period | Treatment Period: Relamorelin 10 μg | 18.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03420781/results